1h Free Analyst Time
The Antibody Fragments Market size was estimated at USD 7.72 billion in 2023, USD 8.07 billion in 2024, and is expected to grow at a CAGR of 4.36% to reach USD 10.42 billion by 2030. Speak directly to the analyst to clarify any post sales queries you may have.
Antibody fragments refer to parts of antibodies capable of binding to specific types of antigens, the foreign substances in the body that induce an immune response. Antibody fragments are usually derivatives from whole antibodies and are developed through enzyme digestion or genetic engineering techniques. The primary driver of this market development is the increasing adoption of targeted therapies for treating chronic conditions, such as autoimmune diseases. Advancements in genetic and biochemical technologies have also paved the way for enhanced production and engineering of these fragments, boosting growth. A constant increase in R&D funding and robust healthcare infrastructure, especially in developed countries, contributed to overall market growth. However, the high costs of producing and purifying antibody fragments can restrict market growth. Regulatory challenges and lack of awareness in emerging markets also pose potential growth restrictions. New avenues for potential opportunities include the development of innovative drugs using antibody fragments and their usage in untapped disease areas. Additionally, the expansion and consolidation of pharmaceutical and biotechnological efforts in emerging markets also present significant opportunities for growth in the antibody fragments market.
Regional Insights
The Americas has a significant landscape in the antibody fragments market owing to ongoing research initiatives that pave the way for the market's growth. The purchasing behavior in these countries is predominantly driven by the advent of personalized medicine, with a notable focus on disease-specific applications. With the rising private and government entities' investments in next-generation healthcare technologies, further growth is anticipated. Europe, the Middle East, and Africa (EMEA) exhibit a burgeoning market for antibody fragments, driven by a rise in health consciousness and governmental initiatives for public health. The increase in lifestyle diseases in these regions has necessitated innovative therapeutics in the healthcare sector. EU countries and the Middle East are experiencing heavy investments in diagnostic technologies and research, thus promising market potential. The Asia Pacific region, home to emerging healthcare influencers, is witnessing a growing demand for antibody fragments. Increased investments in research & development in the field indicate a promising market growth in this region. The customer behavior in this region reveals an inclination towards therapeutic applications, which many manufacturers are looking to capitalize on, further increasing the market growth in the area.FPNV Positioning Matrix
The FPNV Positioning Matrix is pivotal in evaluating the Antibody Fragments Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).Market Share Analysis
The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Antibody Fragments Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.Key Company Profiles
The report delves into recent significant developments in the Antibody Fragments Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Adaptimmune Therapeutics PLC, Aenova Group GmbH, Almac Group, Amgen Inc., Antikor Biopharma, Astellas Pharma Inc., Baxter International Inc., Biogen Inc., Bristol-Myers Squibb Company, Confo Therapeutics, Dyne Therapeutics, Eli Lilly and Company, Evonik Industries AG, F. Hoffmann-La Roche Ltd., Genentech, Inc., Gilde Healthcare, Johnson & Johnson Services, Inc., MoonLake Immunotherapeutics AG, Novartis AG, Numab AG, Pfizer Inc., Sanofi S.A., Takeda Pharmaceutical Company Limited, and Thermo Fisher Scientific Inc.Market Segmentation & Coverage
This research report categorizes the Antibody Fragments Market to forecast the revenues and analyze trends in each of the following sub-markets:- Type
- F(ab) Fragments
- F(ab’)2 Fragments
- Single Domain Antibody Fragments (sdAbs)
- Single-chain Variable Fragments (scFvs)
- Antibody Type
- Monoclonal
- Polyclonal
- Application
- Cancer
- Immunodeficiencies
- Region
- Americas
- Argentina
- Brazil
- Canada
- Mexico
- United States
- California
- Florida
- Illinois
- New York
- Ohio
- Pennsylvania
- Texas
- Asia-Pacific
- Australia
- China
- India
- Indonesia
- Japan
- Malaysia
- Philippines
- Singapore
- South Korea
- Taiwan
- Thailand
- Vietnam
- Europe, Middle East & Africa
- Denmark
- Egypt
- Finland
- France
- Germany
- Israel
- Italy
- Netherlands
- Nigeria
- Norway
- Poland
- Qatar
- Russia
- Saudi Arabia
- South Africa
- Spain
- Sweden
- Switzerland
- Turkey
- United Arab Emirates
- United Kingdom
- Americas
The report offers valuable insights on the following aspects:
- Market Penetration: It presents comprehensive information on the market provided by key players.
- Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
- Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
- Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
- Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.
The report addresses key questions such as:
- What is the market size and forecast of the Antibody Fragments Market?
- Which products, segments, applications, and areas should one consider investing in over the forecast period in the Antibody Fragments Market?
- What are the technology trends and regulatory frameworks in the Antibody Fragments Market?
- What is the market share of the leading vendors in the Antibody Fragments Market?
- Which modes and strategic moves are suitable for entering the Antibody Fragments Market?
Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report
Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.
With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.
This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.
Table of Contents
1. Preface
2. Research Methodology
4. Market Overview
5. Market Insights
6. Antibody Fragments Market, by Type
7. Antibody Fragments Market, by Antibody Type
8. Antibody Fragments Market, by Application
9. Americas Antibody Fragments Market
10. Asia-Pacific Antibody Fragments Market
11. Europe, Middle East & Africa Antibody Fragments Market
12. Competitive Landscape
13. Competitive Portfolio
14. Appendix
List of Figures
List of Tables
Companies Mentioned
- AbbVie Inc.
- Adaptimmune Therapeutics PLC
- Aenova Group GmbH
- Almac Group
- Amgen Inc.
- Antikor Biopharma
- Astellas Pharma Inc.
- Baxter International Inc.
- Biogen Inc.
- Bristol-Myers Squibb Company
- Confo Therapeutics
- Dyne Therapeutics
- Eli Lilly and Company
- Evonik Industries AG
- F. Hoffmann-La Roche Ltd.
- Genentech, Inc.
- Gilde Healthcare
- Johnson & Johnson Services, Inc.
- MoonLake Immunotherapeutics AG
- Novartis AG
- Numab AG
- Pfizer Inc.
- Sanofi S.A.
- Takeda Pharmaceutical Company Limited
- Thermo Fisher Scientific Inc.
Methodology
LOADING...
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 181 |
| Published | March 2024 |
| Forecast Period | 2024 - 2030 |
| Estimated Market Value ( USD | $ 8.07 Billion |
| Forecasted Market Value ( USD | $ 10.42 Billion |
| Compound Annual Growth Rate | 4.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 25 |
